biotime inc (BTX) Key Developments
BioTime, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2015
Aug 10 15
BioTime, Inc. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $2,009,000, loss from operations of $13,496,000, loss before income tax benefit of $13,267,000, net loss attributable to company common shareholders of $9,743,000 or $0.12 per basic and diluted share compared to the total revenues of $1,107,000, loss from operations of $13,062,000, loss before income tax benefit of $12,907,000, net loss attributable to company common shareholders of $9,554,000 or $0.16 per basic and diluted share for the same quarter a year ago.
For the six months period, the company reported total revenues of $3,268,000, loss from operations of $27,005,000, loss before income tax benefit of $27,049,000, net loss attributable to company common shareholders of $19,917,000 or $0.25 per basic and diluted share compared to the total revenues of $2,173,000, loss from operations of $24,183,000, loss before income tax benefit of $23,967,000, net loss attributable to company common shareholders of $17,643,000 or $0.29 per basic and diluted share for the same period a year ago.
BioTime, Inc., Annual General Meeting, Jul 10, 2015
Jun 11 15
BioTime, Inc., Annual General Meeting, Jul 10, 2015., at 10:30 US Eastern Standard Time. Location: 1221 Avenue of the Americas. Agenda: To elect ten directors to hold office until the next annual meeting of shareholders and until their respective successors are duly elected and qualified; to ratify the appointment of OUM & Co. LLP as the company's independent registered public accountants for the fiscal year ending December 31, 2015; to approve certain amendments to the BioTime Equity Incentive Plan; to hold an advisory vote on executive compensation; and to transact such other business as may properly come before the meeting or any adjournments of the meeting.
BioTime, Inc. and OncoCyte Corporation Announce Positive Interim Results from Lung Cancer Study
Jun 4 15
BioTime, Inc. and OncoCyte Corporation have announced positive interim clinical results demonstrating the high level of observed sensitivity and specificity in the assayed samples of a simple blood-based test designed for the early detection of lung cancer. The large, prospective clinical study was conducted by The Wistar Institute. The test was developed in the laboratory of Louise Showe, PhD, professor in the Molecular and Cellular Oncogenesis program of The Wistar Institute's NCI-designated cancer center. As part of the study, clinical investigators used a simple collection system that is approved by the FDA to prepare over 600 peripheral blood samples from patients determined to be at high risk for developing lung cancer based on age and smoking history. These patients were undergoing either low-dose computed tomography (CT) scanning for lung cancer or were recently diagnosed with lung cancer. Wistar scientists then assessed the expression of messenger RNA and micro RNA in the initial training set of 242 samples and developed a classifier of 145 markers (125 mRNAs plus 20 micro RNAs) that most accurately distinguished patients with malignant nodules from those with benign or no findings. The classifier was then assessed in an independent test set of 103 samples. Performance of the classifier was evaluated using several criteria, including Receiver Operating Characteristic (ROC) area under the curve (AUC) analysis, and yielded an AUC of 0.88 (sensitivity of 76% with a specificity of 88%) in the test set. Analysis of the full patient sample set is near completion. In October 2013, OncoCyte entered into a Sponsored Research Agreement with The Wistar Institute to identify, develop and test potential lung cancer biomarkers collaboratively with Dr. Showe's laboratory. OncoCyte has exercised options to obtain exclusive licenses to any inventions, discoveries or technology developed in the course of the collaborative research, including the technology presented and expects to negotiate definitive license agreements with Wistar.
BioTime, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 03:00 PM
May 14 15
BioTime, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 03:00 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Michael D. West, Chief Executive Officer, President and Director.
BioTime, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015
May 11 15
BioTime, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total consolidated revenues of $1,264,454 against $1,066,635 million in the first quarter 2014. Net loss attributable to the company was $10,167,368 or $0.13 per basic and diluted share against $8,099,014 or $0.14 per basic and diluted share a year ago. Loss before income tax benefits was $13,766,937 against $11,077,057 a year ago.